These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 21258010)

  • 1. The importance of neovascularization and its inhibition for allogeneic hematopoietic stem cell transplantation.
    Penack O; Socié G; van den Brink MR
    Blood; 2011 Apr; 117(16):4181-9. PubMed ID: 21258010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth.
    Penack O; Henke E; Suh D; King CG; Smith OM; Na IK; Holland AM; Ghosh A; Lu SX; Jenq RR; Liu C; Murphy GF; Lu TT; May C; Scheinberg DA; Gao DC; Mittal V; Heller G; Benezra R; van den Brink MR
    J Natl Cancer Inst; 2010 Jun; 102(12):894-908. PubMed ID: 20463307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
    Porter DL; Luger SM; Duffy KM; Stadtmauer EA; Laport G; Schuster SJ; Orloff G; Tsai D; McDaid K; Kathakali A; Leonard DG; Antin JH
    Biol Blood Marrow Transplant; 2001; 7(4):230-8. PubMed ID: 11349810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects.
    Carniti C; Gimondi S; Vendramin A; Recordati C; Confalonieri D; Bermema A; Corradini P; Mariotti J
    Clin Cancer Res; 2015 Aug; 21(16):3740-9. PubMed ID: 25977345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma.
    Maloney DG
    Leuk Lymphoma; 2003; 44 Suppl 3():S99-105. PubMed ID: 15202532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
    Shimoni A; Nagler A
    Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.
    Du W; Cao X
    Front Immunol; 2018; 9():2979. PubMed ID: 30631325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT.
    Karimi MA; Bryson JL; Richman LP; Fesnak AD; Leichner TM; Satake A; Vonderheide RH; Raulet DH; Reshef R; Kambayashi T
    Blood; 2015 Jun; 125(23):3655-63. PubMed ID: 25788701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytolytic pathways in haematopoietic stem-cell transplantation.
    van den Brink MR; Burakoff SJ
    Nat Rev Immunol; 2002 Apr; 2(4):273-81. PubMed ID: 12001998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S1PR5 regulates NK cell responses in preventing graft-versus-host disease while preserving graft-versus-tumour activity in a murine allogeneic haematopoietic stem cell transplantation model.
    Wang F; Zhao S; Gu Z; Zhao X; Yang N; Guan L; Liu T; Wang L; Fang S; Zhu C; Luo L; Li M; Wang L; Gao C
    Hematol Oncol; 2020 Feb; 38(1):89-102. PubMed ID: 31465552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute graft-vs-host disease: pathobiology and management.
    Goker H; Haznedaroglu IC; Chao NJ
    Exp Hematol; 2001 Mar; 29(3):259-77. PubMed ID: 11274753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.
    Stelljes M; Strothotte R; Pauels HG; Poremba C; Milse M; Specht C; Albring J; Bisping G; Scheffold C; Kammertoens T; Oelmann E; Silling G; Berdel WE; Kienast J
    Blood; 2004 Aug; 104(4):1210-6. PubMed ID: 15090450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.
    Stelljes M; Specht C; Albring J; Volkmann S; Schlösser V; Pauels HG; Poremba C; Bisping G; Opitz C; Scheffold C; Silling G; Kiehl M; Berdel WE; Kienast J
    Transplantation; 2007 Feb; 83(3):314-22. PubMed ID: 17297406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
    Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
    Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunobiology of allogeneic hematopoietic stem cell transplantation.
    Welniak LA; Blazar BR; Murphy WJ
    Annu Rev Immunol; 2007; 25():139-70. PubMed ID: 17129175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial Deacetylase SIRT3 Plays an Important Role in Donor T Cell Responses after Experimental Allogeneic Hematopoietic Transplantation.
    Toubai T; Tamaki H; Peltier DC; Rossi C; Oravecz-Wilson K; Liu C; Zajac C; Wu J; Sun Y; Fujiwara H; Henig I; Kim S; Lombard DB; Reddy P
    J Immunol; 2018 Dec; 201(11):3443-3455. PubMed ID: 30389773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
    Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD.
    Blazar BR; Hill GR; Murphy WJ
    Nat Rev Clin Oncol; 2020 Aug; 17(8):475-492. PubMed ID: 32313224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.